Literature DB >> 16132878

[Differential diagnoses of acute bilateral hearing loss in a patient with metastatic bronchial carcinoma].

P Halleck1, A Haisch, B Sedlmaier.   

Abstract

The first symptom of an acoustic neuroma in about 50% of the patients is hearing loss, which occurs suddenly in about 5-10% of cases. Acute progressive hearing loss is associated with a broad spectrum of differential diagnoses. Cerebellar and hepatic metastases from a bronchial carcinoma were previously diagnosed in the case presented here, and the most probable causes of the progressive hearing loss, e.g. idiopathic sudden deafness, infection and tumor-associated factors, were considered and diagnostically analyzed. The discussion ultimately focused on the clinical and radiological signs of bilateral acoustic neuroma. The patient's history and clinical findings yielded no indication of neurofibromatosis (type 1/2). Nevertheless, the constellation of findings suggests that the bilateral hearing loss was caused by a bilateral acoustic neuroma.

Entities:  

Mesh:

Year:  2006        PMID: 16132878     DOI: 10.1007/s00106-005-1317-z

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  4 in total

1.  Bilateral irreversible hearing loss associated with the combination of carboplatin and paclitaxel chemotherapy: a unusual side effect.

Authors:  F Salvinelli; M Casale; B Vincenzi; D Santini; V Di Peco; L Firrisi; N Onori; F Greco; G Tonini
Journal:  J Exp Clin Cancer Res       Date:  2003-03

Review 2.  [Paraneoplastic cerebral syndromes with oto-neuro-ophthalomologic manifestations].

Authors:  J Dalmau; J Porta-Etessam
Journal:  Rev Neurol       Date:  2000 Dec 16-31       Impact factor: 0.870

3.  [Medical palliative therapy of meningiosis carcinomatosa of breast carcinoma with dissociated response in lumbar methotrexate instillation].

Authors:  M Brauckhoff; M Kamprad; J Steuber
Journal:  Med Klin (Munich)       Date:  2001-09-15

4.  Sequence variations of mitochondrial DNA and individual sensitivity to the ototoxic effect of cisplatin.

Authors:  Ulrike Peters; S Preisler-Adams; Claudia Lanvers-Kaminsky; Heribert Jürgens; Antoinette Lamprecht-Dinnesen
Journal:  Anticancer Res       Date:  2003 Mar-Apr       Impact factor: 2.480

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.